237385-15-8

Basic information

• Product Name: Methyl 4-broMo-5-Methylthiophene-2-carboxylate
• Synonyms: Methyl 4-broMo-5-Methylthiophene-2-carboxylate;4-BROMO-5-METHYL-2-THIOPHENECARBOXYLIC ACID METHYL ESTER
• CAS NO: 237385-15-8
• Molecular Formula: C₇H₇BrO₂S
• Molecular Weight: 235.09828
• Mol File: 237385-15-8.mol

Chemical Properties

• Boiling Point: 277.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.575±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 4-broMo-5-Methylthiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-broMo-5-Methylthiophene-2-carboxylate(237385-15-8)
• EPA Substance Registry System: Methyl 4-broMo-5-Methylthiophene-2-carboxylate(237385-15-8)

Safety Data

• Hazardous Substances Data: 237385-15-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 4-bromo-5-methylthiophene-2-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals and chemicals. Its unique structure and reactivity contribute to the development of new compounds with potential applications in medicine and other industries.
Used in Pharmaceutical Production:
In the pharmaceutical industry, Methyl 4-bromo-5-methylthiophene-2-carboxylate is utilized as a building block for the creation of novel drug molecules. Its incorporation into these molecules can enhance their therapeutic properties, leading to the development of more effective treatments for various diseases and conditions.
Safety Precautions:
Due to its reactive nature and potential hazardous impact on human health and the environment, it is crucial to follow proper safety precautions when handling and disposing of Methyl 4-bromo-5-methylthiophene-2-carboxylate. This includes the use of appropriate personal protective equipment, working in well-ventilated areas, and adhering to established disposal protocols.

Upstream product

• 29421-99-6 4-bromo-5-methyl-thiophene-2-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 7311-63-9 5-bromothiophene-2-carboxylic acid 
• 67-56-1 methanol 
• 1445-45-0 Trimethyl orthoacetate 
• 1918-79-2 2-methylthiophene-5-carboxylic acid 
• 19432-69-0 methyl 5-methylthiophene-2-carboxylate 
• 29421-73-6 3,5-dibromo-2-methylthiophene 

Downstream Products

• 302777-34-0 2-(4-bromo-5-methyl-2-thienyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole 
• 302777-32-8 1-(4-bromo-5-methyl-2-thienoyl)-2-(4-methoxybenzoyl)hydrazine 
• 302777-36-2 1,2-bis{2-methyl-5-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-3-thienyl}hexafluorocyclopentene 
• 237385-20-5 methyl 4-[4-(3,4-dimethoxyphenyl)(1,3-thiazol-2-yl)]-5-methylthiophene-2-carboxylate 
• 288398-45-8 Methyl 5-methyl-4-(phenylamino)thiophene-2-carboxylate 
• 1109284-49-2 methyl 5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylate 
• 1239576-74-9 methyl 5-methyl-4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-thiophenecarboxylate 
• 1047644-69-8 N-[(1S)-2-amino-1-(cyclohexylmethyl)ethyl]-5-methyl-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047644-68-7 N-[(1S)-2-amino-1-(cyclohexylmethyl)ethyl]-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide 
• 1047627-27-9 N-[(1S)-2-amino-1-(cyclohexylmethyl)ethyl]-4-(4-bromo-1-methyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide 
• 1047645-94-2 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(1,4-dimethyl-1H-pyrazol-5-yl)-5-methyl-2-thiophenecarboxamide 
• 1047627-35-9 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-methyl-4-[1-methyl-4-(1-methylethyl)-1H-pyrazol-5-yl]-2-thiophenecarboxamide 
• 1047627-39-3 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-methyl-4-(1-methyl-4-propyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047646-06-9 N-{(1S)-2-cyclohexyl-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]ethyl}-5-methyl-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 

Relevant articles and documents

PKB inhibitor

The invention provides a PKB inhibitor, particularly relates to a compound shown as a formula I or a pharmaceutically acceptable salt thereof. The invention further provides a preparation method of the compound.

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

In-Depth Assessment of the Palladium-Catalyzed Fluorination of Five-Membered Heteroaryl Bromides

A thorough investigation of the challenging Pd-catalyzed fluorination of five-membered heteroaryl bromides is presented. Crystallographic studies and density functional theory (DFT) calculations suggest that the challenging step of this transformation is

INHIBITORS OF AKT ACTIVITY

Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS

The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.

PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS

The invention encompasses pyrazolo[1,5-a]pyridine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.

PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES

Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.

INTEGRASE INHIBITORS 3

The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.

Compounds and compositons for treating C1s-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.